The present disclosure provides antagonist fusion polypeptides (e.g., with extended half-life, improved antagonist activity) comprising (i) a serum albumin binding polypeptide; (ii) a polypeptide hormone analog capable of antagonizing its receptor activation; and (iii) a linker, as well as various related technologies including, methods of producing and using such fusion polypeptides.